Does RITLECITINIB Cause Product dose omission issue? 45 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Product dose omission issue have been filed in association with RITLECITINIB (Litfulo). This represents 3.1% of all adverse event reports for RITLECITINIB.
45
Reports of Product dose omission issue with RITLECITINIB
3.1%
of all RITLECITINIB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Product dose omission issue From RITLECITINIB?
Of the 45 reports.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RITLECITINIB. However, 45 reports have been filed with the FAERS database.
What Other Side Effects Does RITLECITINIB Cause?
Drug ineffective (259)
Therapeutic product effect incomplete (122)
Condition aggravated (85)
Off label use (82)
Headache (70)
Diarrhoea (49)
Alopecia (44)
Fatigue (36)
Urticaria (36)
Acne (35)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which RITLECITINIB Alternatives Have Lower Product dose omission issue Risk?
RITLECITINIB vs RITODRINE
RITLECITINIB vs RITONAVIR
RITLECITINIB vs RITUXAN
RITLECITINIB vs RITUXIMAB
RITLECITINIB vs RITUXIMAB-ABBS